How are NKTR collar max profit and max loss calculated?

Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium. For the NKTR collar priced from the end-of-day chain at a 30-day expiry (ATM IV 56.90%), the computed maximum profit is $560.50 per contract and the computed maximum loss is -$439.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a NKTR collar?

The breakeven for the NKTR collar priced on this page is roughly $69.40 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current NKTR market-implied 1-standard-deviation expected move is approximately 16.31%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current NKTR implied volatility affect this collar?

NKTR ATM IV is at 56.90% with IV rank near 3.34%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

NKTR Collar Strategy

NKTR (Nektar Therapeutics), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.

NKTR (Nektar Therapeutics) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.48B, a beta of 1.25 versus the broader market, a 52-week range of 7.99-109, average daily share volume of 1.1M, a public-listing history dating back to 1994, approximately 61 full-time employees. These structural characteristics shape how NKTR stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.25 places NKTR roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.

What is a collar on NKTR?

A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot.

Current NKTR snapshot

As of May 15, 2026, spot at $70.12, ATM IV 56.90%, IV rank 3.34%, expected move 16.31%. The collar on NKTR below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this collar structure on NKTR specifically: IV regime affects collar pricing on both sides; compressed NKTR IV at 56.90% typically pushes the short call premium to roughly offset the long put cost, with a market-implied 1-standard-deviation move of approximately 16.31% (roughly $11.44 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated NKTR expiries trade a higher absolute premium for lower per-day decay. Position sizing on NKTR should anchor to the underlying notional of $70.12 per share and to the trader's directional view on NKTR stock.

NKTR collar setup

The NKTR collar below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With NKTR near $70.12, the first option leg uses a $75.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed NKTR chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 NKTR shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 100 shares	Stock	$70.12	long
Sell 1	Call	$75.00	$3.08
Buy 1	Put	$65.00	$2.35

NKTR collar risk and reward

Net Premium / Debit: -$6,939.50
Max Profit (per contract): $560.50
Max Loss (per contract): -$439.50
Breakeven(s): $69.40
Risk / Reward Ratio: 1.275

Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium.

NKTR collar payoff curve

Modeled P&L at expiration across a range of underlying prices for the collar on NKTR. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	-$439.50
$15.51	-77.9%	-$439.50
$31.02	-55.8%	-$439.50
$46.52	-33.7%	-$439.50
$62.02	-11.5%	-$439.50
$77.52	+10.6%	+$560.50
$93.03	+32.7%	+$560.50
$108.53	+54.8%	+$560.50
$124.03	+76.9%	+$560.50
$139.54	+99.0%	+$560.50

When traders use collar on NKTR

Collars on NKTR hedge an existing long NKTR stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.

NKTR thesis for this collar

The market-implied 1-standard-deviation range for NKTR extends from approximately $58.68 on the downside to $81.56 on the upside. A NKTR collar hedges an existing long NKTR position with a protective put while financing the put cost via a short call; when the premiums roughly offset, the collar acts as a near-zero-cost insurance band around the current spot. Current NKTR IV rank near 3.34% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on NKTR at 56.90%. As a Healthcare name, NKTR options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to NKTR-specific events.

NKTR collar positions are structurally neutral (protective); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. NKTR positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move NKTR alongside the broader basket even when NKTR-specific fundamentals are unchanged. Always rebuild the position from current NKTR chain quotes before placing a trade.

Frequently asked questions

What is a collar on NKTR?: A collar on NKTR is the collar strategy applied to NKTR (stock). The strategy is structurally neutral (protective): A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot. With NKTR stock trading near $70.12, the strikes shown on this page are snapped to the nearest listed NKTR chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are NKTR collar max profit and max loss calculated?: Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium. For the NKTR collar priced from the end-of-day chain at a 30-day expiry (ATM IV 56.90%), the computed maximum profit is $560.50 per contract and the computed maximum loss is -$439.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a NKTR collar?: The breakeven for the NKTR collar priced on this page is roughly $69.40 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current NKTR market-implied 1-standard-deviation expected move is approximately 16.31%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a collar on NKTR?: Collars on NKTR hedge an existing long NKTR stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
How does current NKTR implied volatility affect this collar?: NKTR ATM IV is at 56.90% with IV rank near 3.34%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.